Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - CADENCE PHARMACEUTICALS INC | Financial_Report.xls |
| 10-K - FORM 10-K - CADENCE PHARMACEUTICALS INC | d268600d10k.htm |
| EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - CADENCE PHARMACEUTICALS INC | d268600dex321.htm |
| EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - CADENCE PHARMACEUTICALS INC | d268600dex312.htm |
| EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - CADENCE PHARMACEUTICALS INC | d268600dex311.htm |
| EX-10.17 - SECOND AMENDMENT TO LEASE - CADENCE PHARMACEUTICALS INC | d268600dex1017.htm |
| EX-10.16 - FIRST AMENDMENT TO LEASE - CADENCE PHARMACEUTICALS INC | d268600dex1016.htm |
| EX-10.11 - 2012 CORPORATE BONUS PLAN - CADENCE PHARMACEUTICALS INC | d268600dex1011.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-171396, 333-163941 and 333-138226) and Form S-3 (Nos. 333-173295, 333-170538, 333-161756, 333-158126 and 333-147721) of Cadence Pharmaceuticals, Inc. and in the related Prospectuses of our reports dated March 13, 2012, with respect to the financial statements, and the effectiveness of internal control over financial reporting of Cadence Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2011.
/s/ Ernst & Young LLP
San Diego, California
March 13, 2012